IDEAS home Printed from https://ideas.repec.org/a/spr/hecrev/v4y2014i1p1-1510.1186-s13561-014-0006-6.html
   My bibliography  Save this article

A comparison of the cost-effectiveness of treatment of prolonged acute convulsive epileptic seizures in children across Europe

Author

Listed:
  • Dawn Lee
  • Daniel Gladwell
  • Anthony Hatswell
  • Joshua Porter
  • Nic Brereton
  • Elaine Tate
  • Alison Saunders

Abstract

In the majority of children and adolescents with epilepsy, optimal drug therapy adequately controls their condition. However, among the remaining patients who are still uncontrolled despite mono-, bi- or tri-therapy with chronic anti-epileptic treatment, a rescue medication is required. In Western Europe, the licensed medications available for first-line treatment of prolonged acute convulsive seizures (PACS) vary widely, and so comparators for clinical and economic evaluation are not consistent. No European guidelines currently exist for the treatment of PACS in children and adolescents and limited evidence is available for the effectiveness of treatments in the community setting. The authors present cost-effectiveness data for BUCCOLAM® (midazolam oromucosal solution) for the treatment of PACS in children and adolescents in the context of the treatment pathway in seven European countries in patients from 6 months to 18 years. For each country, the health economic model consisted of a decision tree, with decision nodes informed by clinical data and expert opinion obtained via a Delphi methodology. The events modelled are those associated with a patient experiencing a seizure in the community setting. The model assessed the likelihood of medication being administered successfully and of seizure cessation. The associated resource use was also modelled, and ambulance call-outs and hospitalisations were considered. The patient’s quality of life was estimated by clinicians, who completed a five-level EuroQol five dimensions questionnaire from the perspective of a child or adolescent suffering a seizure. Despite differences in current therapy, treatment patterns and healthcare costs in all countries assessed, BUCCOLAM was shown to be cost saving and offered increased health-related benefits for patients in the treatment of PACS compared with the current local standard of care. Copyright Lee et al.; licensee Springer 2014

Suggested Citation

  • Dawn Lee & Daniel Gladwell & Anthony Hatswell & Joshua Porter & Nic Brereton & Elaine Tate & Alison Saunders, 2014. "A comparison of the cost-effectiveness of treatment of prolonged acute convulsive epileptic seizures in children across Europe," Health Economics Review, Springer, vol. 4(1), pages 1-15, December.
    • Handle: RePEc:spr:hecrev:v:4:y:2014:i:1:p:1-15:10.1186/s13561-014-0006-6
    DOI: 10.1186/s13561-014-0006-6
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1186/s13561-014-0006-6
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1186/s13561-014-0006-6?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Catherine Ludwig & Lauri Fisher, 2020. "Buccal Midazolam Solution for the Management of Prolonged Acute Convulsive Seizures: A Cost Analysis," PharmacoEconomics - Open, Springer, vol. 4(1), pages 171-179, March.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:hecrev:v:4:y:2014:i:1:p:1-15:10.1186/s13561-014-0006-6. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/13561 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.